Skip to main content

Table 3 Median CMT at each visit

From: Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings

CMT

Time point

Pre ranibizumab

6 m pre switch

3 m pre switch

Baseline (switch)

3 m post switch

6 m post switch

9 m post switch

12 m post switch

Median (IQR) CMT in μm

461 (417–523)

402 (345–476)

374 (328–431)

400 (358–451)

345 (315–365)

340 (314–391)

357 (321–395)

351 (314–397)

n

57

54

52

57

55

55

49

51

Statistical significance

****

ns

*

 

****

****

***

**

p value

 < 0.0001

0.9404

0.0439

 

 < 0.0001

 < 0.0001

0.0004

0.0011

CMT

Time point

15 m post switch

18 m post switch

21 m post switch

24 m post switch

27 m post switch

30 m post switch

33 m post switch

36 m post switch

Median (IQR) CMT in μm

336 (308- 378)

350 (320- 416)

359 (323- 385)

361 (307- 432)

339 (318- 387)

343 (302- 397)

333 (307- 395)

360 (310- 411)

n

52

52

48

41

37

50

40

57

Statistical significance

****

***

**

ns

***

****

***

*

p value

 < 0.0001

0.0004

0.0039

0.21

0.0003

 < 0.0001

0.0003

0.0107

  1. Central macular thickness (CMT) before the initiation of treatment with ranibizumab, 6 and 3 months before the switch to aflibercept, at the day of the decision to switch and every 3 months after the switch up to 36 months follow-up. CMT was significantly decreased compared to baseline 3 months pre switch and every trimester post switch except in month 24. (Wilcoxon matched-pairs signed rank test)
Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us